Dichloroacetate induces apoptosis in endometrial cancer cells
- PMID: 18423823
- PMCID: PMC2735772
- DOI: 10.1016/j.ygyno.2008.01.038
Dichloroacetate induces apoptosis in endometrial cancer cells
Abstract
Purpose: A recent landmark study demonstrated that Dichloroacetate (DCA) treatment promoted apoptosis in lung, breast, and glioblastoma cancer cell lines by shifting metabolism from aerobic glycolysis to glucose oxidation coupled with NFAT-Kv1.5 axis remodeling. The objective of this study was to determine whether DCA induces apoptosis in endometrial cancer cells and to assess apoptotic mechanism.
Methods: A panel of endometrial cancer cell lines with varying degrees of differentiation was treated with DCA and analyzed for apoptosis via flow cytometry. Biological correlates such as gene expression, intracellular Ca(2+), and mitochondrial membrane potential were examined to assess apoptotic mechanism.
Results: Initiation of apoptosis was observed in five low to moderately invasive cancer cell lines including Ishikawa, RL95-2, KLE, AN3CA, and SKUT1B while treatment had no effect on non-cancerous 293T cells. Two highly invasive endometrial adenocarcinoma cell lines, HEC1A and HEC1B, were found to be resistant to DCA-induced apoptosis. Apoptotic responding cell lines had a significant increase in early and late apoptotis, a decrease in mitochondrial membrane potential, and decreased Survivin transcript abundance, which are consistent with a mitochondrial-regulated mechanism. DCA treatment decreased intracellular calcium levels in most apoptotic responding cell lines which suggests a contribution from the NFAT-Kv1.5-mediated pathway. DCA treatment increased p53 upregulated modulator of apoptosis (PUMA) transcripts in cell lines with an apoptotic response, suggesting involvement of a p53-PUMA-mediated mechanism.
Conclusions: Dichloroacetate effectively sensitizes most endometrial cancer cell lines to apoptosis via mitochondrial, NFAT-Kv1.5, and PUMA-mediated mechanisms. Further investigation of the cancer therapeutic potential of DCA is warranted.
Conflict of interest statement
The authors declare there are no conflicts of interest.
Figures
Similar articles
-
Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.Cancer Lett. 2016 Feb 1;371(1):20-9. doi: 10.1016/j.canlet.2015.11.023. Epub 2015 Nov 23. Cancer Lett. 2016. PMID: 26607904
-
Sodium dichloroacetate selectively _targets cells with defects in the mitochondrial ETC.Int J Cancer. 2010 Dec 1;127(11):2510-9. doi: 10.1002/ijc.25499. Int J Cancer. 2010. PMID: 20533281
-
Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells.Int J Oncol. 2011 Feb;38(2):409-17. doi: 10.3892/ijo.2010.851. Epub 2010 Dec 3. Int J Oncol. 2011. PMID: 21132264
-
[Anti-cancer properties of dichloroacetate].Pol Merkur Lekarski. 2022 Apr 19;50(296):145-147. Pol Merkur Lekarski. 2022. PMID: 35436282 Review. Polish.
-
Dichloroacetate (DCA) as a potential metabolic-_targeting therapy for cancer.Br J Cancer. 2008 Oct 7;99(7):989-94. doi: 10.1038/sj.bjc.6604554. Epub 2008 Sep 2. Br J Cancer. 2008. PMID: 18766181 Free PMC article. Review.
Cited by
-
Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts.Pharmaceuticals (Basel). 2024 Jun 6;17(6):744. doi: 10.3390/ph17060744. Pharmaceuticals (Basel). 2024. PMID: 38931411 Free PMC article. Review.
-
Pyruvate dehydrogenase kinase as a novel therapeutic _target in oncology.Front Oncol. 2013 Mar 7;3:38. doi: 10.3389/fonc.2013.00038. eCollection 2013. Front Oncol. 2013. PMID: 23471124 Free PMC article.
-
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.Invest New Drugs. 2012 Feb;30(1):200-11. doi: 10.1007/s10637-010-9552-x. Epub 2010 Oct 8. Invest New Drugs. 2012. PMID: 20931262
-
Logical modelling reveals the PDC-PDK interaction as the regulatory switch driving metabolic flexibility at the cellular level.Genes Nutr. 2019 Sep 9;14:27. doi: 10.1186/s12263-019-0647-5. eCollection 2019. Genes Nutr. 2019. PMID: 31516637 Free PMC article.
-
Pyruvate dehydrogenase kinase as a potential therapeutic _target for malignant gliomas.Brain Tumor Res Treat. 2013 Oct;1(2):57-63. doi: 10.14791/btrt.2013.1.2.57. Epub 2013 Oct 31. Brain Tumor Res Treat. 2013. PMID: 24904893 Free PMC article. Review.
References
-
- Rose P. Endometrial Carcinoma. New England Journal of Medicine. 1996;335(9):640–649. - PubMed
-
- Ingram SS, Rosenman J, Heath R, Morgan TM, Moore D, Varia M. The predictive value of progesterone receptor levels in endometrial cancer. Int J Radiat Oncol Biol Phys. 1989;17(1):21–27. - PubMed
-
- Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36–44. - PubMed
-
- Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37–51. - PubMed
-
- Chen Z, Lu W, Garcia-Prieto C, Huang P. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr. 2007 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous